Liaoning He Eye Hospital Group (301103.SZ) issues a profit warning, expecting a net loss of 20.5 million to 30.75 million yuan in 2024, turning from profit to loss.
He Medical Ophthalmology (301103.SZ) released the 2024 annual performance forecast, with the company expecting...
Liaoning He Eye Hospital Group (301103.SZ) released the performance forecast for the year 2024, with the company expecting a net loss attributable to shareholders of the listed company of 20.5 million yuan to 30.75 million yuan, a switch from profit to loss; a net loss of 22 million yuan to 32.5 million yuan after deducting non-recurring gains and losses, also a switch from profit to loss.
During the reporting period, intensified industry competition and the impact of healthcare payment reform caused a decrease in the company's revenue and gross profit. The company has invested heavily in innovative business, digitalization, and R&D projects, resulting in increased cost and expense compared to the same period last year.
Related Articles

ZHONGSHENJIANYE (02503): The subscription price has been changed to HKD 0.61 per share. Trading will resume at 1:00 pm on July 3rd.

SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.

SIRNAOMICS-B (02257): Ouyang Yunlong appointed as non-executive director.
ZHONGSHENJIANYE (02503): The subscription price has been changed to HKD 0.61 per share. Trading will resume at 1:00 pm on July 3rd.

SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.

SIRNAOMICS-B (02257): Ouyang Yunlong appointed as non-executive director.

RECOMMEND

U.S. Senate Passes “Big and Beautiful” Bill, Triggering Surge in Gold Amid Soaring Deficit Concerns
02/07/2025

Declining Demand Triggers Price Drop; Photovoltaic Glass Industry May Be Preparing for a New Round of Coordinated Production Cuts
02/07/2025

Surge in Prices of Chinese-Made Goods Highlights Tariff Impact on U.S. Consumers
02/07/2025